Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
If you are interested in meeting with the Protagonist team during the conference, please reach out to your H.C. Wainwright representative.NEWARK, CA / ACCESSWIRE / September 3, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY.
2024年9月3日，智能治療公司（納斯達克代碼：PTGX）（以下簡稱「智能治療」或「公司」）宣佈，總裁兼首席執行官Dinesh V. Patel博士將在紐約的H.C. Wainwright第26屆全球投資博覽會上參加座談會和一對一會議。
H.C. Wainwright 26th Annual Global Investment Conference - September 9-11, 2024
H.C. Wainwright第26屆全球投資會議-2024年9月9日至11日
Format: Fireside Chat
Day/Time: Tuesday, September 10 at 1:30 P.M. ET
Webcast:
形式：爐邊聊天
日期/時間：9月10日星期二 下午1:30 ET
網絡直播：
If you are interested in meeting with the Protagonist team during the conference, please reach out to your H.C. Wainwright representative.
如果您有興趣在會議期間與智能治療團隊會面，請聯繫您的H.C. Wainwright代表。
About Protagonist
關於主角
Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities (NCEs) rusfertide and JNJ-2113 (formerly PN-235) in advanced Phase 3 stages of clinical development, both derived from the Company's proprietary technology platform. Protagonist and Johnson & Johnson (JNJ) scientists jointly discovered JNJ-2113 as part of Protagonist's Interleukin-23 receptor (IL-23R) antagonist collaboration with JNJ and followed it through IND-enabling pre-clinical and Phase 1 studies, with JNJ assuming responsibility for further clinical development. JNJ-2113 is currently being pursued in five Phase 3 studies in psoriasis, and a Phase 2b study in ulcerative colitis. Rusfertide, a mimetic of the natural hormone hepcidin, is the Company's lead drug candidate currently in a global Phase 3 development program for polycythemia vera (PV). The randomized portion of the Phase 2 REVIVE study has been successfully completed, and results were published in The New England Journal of Medicine in February 2024. The open-label extension (OLE) component of REVIVE has also been completed and is followed by an additional 2-year long-term extension (LTE) THRIVE study. Enrollment has been completed in the global Phase 3 VERIFY study of rusfertide in polycythemia vera. Rusfertide is being co-developed and co-commercialized with Takeda pursuant to a worldwide collaboration and license agreement with Takeda announced in January 2024.
Protagonist Therapeutics是一家生物製藥公司，擁有基於肽的新化學實體（NCE）rusfertide和JNJ-2113（原名PN-235），處於臨床開發的先進第3階段，這兩種藥物都來自公司的專有技術平台。Protagonist和強生（JNJ）的科學家在合作中共同發現了JNJ-2113，隨後進行了IND前臨床和第1期研究，JNJ則負責進一步的臨床開發。JNJ-2113目前正在進行五項銀屑病第3期研究和一項潰瘍性結腸炎第20億階段的研究。 Rusfertide作爲一種天然荷爾蒙hepcidin的類似物，是該公司的股票候選藥物，目前正在進行全球第3期開發計劃，用於紅細胞增多症。第2期REVIVE研究的隨機部分已經成功完成，並於2024年2月發表於《新英格蘭醫學雜誌》中。REVIVE的開放標籤延伸（OLE）組分還已經完成，並隨後是另外的2年長期延伸（LTE）THRIVE研究。rusfertide的全球第3期VERIFY試驗的招募已經完成。rusfertide正在與武田共同開發和銷售，根據於2024年1月宣佈的全球合作和許可協議。
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at .
有關Protagonist，其管道藥物候選和臨床研究的更多信息可在該公司的網站上找到。
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
投資者關係聯繫人
Corey Davis，博士。
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
Media Contact
Virginia Amann, Founder/CEO
ENTENTE Network of Companies
virginiaamann@ententeinc.com
媒體聯繫人
Virginia Amann，創始人/首席執行官
ENTENTE公司網絡
virginiaamann@ententeinc.com
SOURCE: Protagonist Therapeutics, Inc.
消息來源：Protagonist Therapeutics，Inc。